Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Key Terms

severe hypertriglyceridemia medical

An extreme elevation of triglycerides, the fat particles carried in the blood, that can overwhelm the body’s ability to process them and sharply raise the risk of acute pancreatitis and other complications. Think of blood as a river and triglycerides as oil — when levels get too high the flow and nearby organs can be damaged. Investors care because it drives demand for treatments, affects clinical trial safety and regulatory review, and can influence healthcare costs, reimbursement and company valuations.

acute pancreatitis medical

Acute pancreatitis is a sudden inflammation of the pancreas that typically causes severe abdominal pain, nausea and often requires hospitalization; in serious cases it can lead to organ failure or prolonged treatment. Investors should care because sudden spikes in cases or breakthroughs in treatment affect hospital admissions, drug and device demand, insurance payouts and clinical-trial outcomes — like an unexpected house fire that forces emergency repairs and shifts spending priorities.

chylomicronemia medical

Chylomicronemia is a medical condition where very large fat-carrying particles called chylomicrons build up in the bloodstream, causing extremely high levels of blood fats (triglycerides). Investors care because this rare but serious disorder drives demand for diagnostics, treatments and hospital care, influences clinical trial outcomes and regulatory reviews, and can affect revenue and risk for companies in pharmaceuticals, biotech, insurers and medical services — think of it as clogged pipes in the body that create costly, urgent needs for solutions.

monte carlo simulation technical

A Monte Carlo simulation is a computerized way to model many possible future outcomes by running thousands of randomized “what-if” scenarios, like rolling dice repeatedly to see the range of results. For investors it shows the probability of different returns, losses, or timing outcomes under varied assumptions, helping quantify uncertainty and compare risk — similar to using many practice runs to judge how often a plan succeeds or fails.

View in glossary

subcutaneous medical

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

sirna medical

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

central nervous system medical

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Piper Sandler 37th Annual Healthcare Conference – December 2-4, 2025

Type: Fireside Chat Presentation
Date/Time: December 3, 2025, 10:30 a.m. EST

8th Annual Evercore Healthcare Conference – December 2-4, 2025

Type: Fireside Chat Presentation
Date/Time: December 4, 2025, 10:00 a.m. EST

World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) – December 4-6, 2025

Title: Baseline Characteristics and Rationale of the SHASTA-3 and SHASTA-4 Phase 3 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Presenter: Norman Lepore

Title: Recurrent Hospital Admissions in Acute Pancreatitis and Persistent Chylomicronemia
Presenter: Rohit Loomba

Title: A Monte Carlo Simulation Comparing TG Lowering with Plozasiran versus Olezarsan in Patients with FCS
Presenter: Nihar Desai

Title: Plozasiran Decreases the Risk of AP and may Improve QOL in FCS
Encore Presentation

Title: A Randomized Placebo Controlled Phase 3 Study of Plozasiran in Patients with FCS: Palisade 1-Year OLE
Encore Presentation

7th Annual CNS Delivery Summit – December 9-11, 2025

Title: TRiM^TM platform for subcutaneous delivery of siRNA to Central Nervous System
Date/Time: December 10, 2025, 9:30 am EST
Presenter: Agnieszka Glebocka

Presentation materials and webcast links, if available/applicable, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251201268006/en/

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com

Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com

Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com

Source: Arrowhead Pharmaceuticals, Inc.